Additional file 1 of Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis

Autor: Kreuter, Michael, Picker, Nils, Schwarzkopf, Larissa, Baumann, Severin, Cerani, Agustin, Postema, Roelien, Maywald, Ulf, Dittmar, Axel, Langley, Jonathan, Patel, Haridarshan

Additional file 1: Table S1. ICD-10-GM codes for study exclusion. Table S2. Charlson Comorbidity Index. Table S3. ATC/OPS/ICD-10-GM codes for baseline characteristics. Table S4. OPS codes for disease deterioration proxies.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d6addb218021464d829828737b9c116

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds.

Autor: Wilke T; IPAM e.V., Wismar, Germany., Picker N; Ingress-Health HWM GmbH, Wismar, Germany., Müller S; Ingress-Health HWM GmbH, Wismar, Germany., Stürmlinger A; Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany., Deiters B; GWQ ServicePlus AG, Düsseldorf, Germany., Dittmar A; IPAM e.V., Wismar, Germany., Aberle J; Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany., Gabler M; Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany.

Publikováno v: ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2022 May 02; Vol. 14, pp. 319-332. Date of Electronic Publication: 2022 May 02 (Print Publication: 2022).